Průtoková cytometrie - publikace

Vybrané publikace

[1]  R. Greil, P. Obrtlíková, L. Smolej, T. Kozák, M. Steurer, J. Andel, S. Burgstaller, E. Mikušková, L. Gercheva, T. Nösslinger, T. Papajík, M. Ladická, M. Girschikofsky, M. Hrubiško, U. Jäger, M. Fridrik, M. Pecherstorfer, E. Králiková, C. Burcoveanu, E. Spasov, A. Petzer, G. Mihaylov, J. Raynov, H. Oexle, A. Zabernigg, E. Flochová, S. Palášthy, O. Stehlíková, M. Doubek, P. Altenhofer, L. Pleyer, T. Melchardt, A. Klingler, J. Mayer, and A. Egle, “Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial,” Lancet Haematol, vol. 3, no. 7, pp. e317-329, Jul. 2016.

[2]  A. C. Rawstron, C. Fazi, A. Agathangelidis, N. Villamor, R. Letestu, J. Nomdedeu, C. Palacio, O. Stehlikova, K.-A. Kreuzer, S. Liptrot, D. O’Brien, R. M. de Tute, I. Marinov, M. Hauwel, M. Spacek, J. Dobber, A. P. Kater, P. Gambell, A. Soosapilla, G. Lozanski, G. Brachtl, K. Lin, J. Boysen, C. Hanson, J. L. Jorgensen, M. Stetler-Stevenson, C. Yuan, H. E. Broome, L. Rassenti, F. Craig, J. Delgado, C. Moreno, F. Bosch, A. Egle, M. Doubek, S. Pospisilova, S. Mulligan, D. Westerman, C. M. Sanders, R. Emerson, H. S. Robins, I. Kirsch, T. Shanafelt, A. Pettitt, T. J. Kipps, W. G. Wierda, F. Cymbalista, M. Hallek, P. Hillmen, E. Montserrat, and P. Ghia, “A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study,” Leukemia, Dec. 2015.

[3]  J. Chovancová, T. Bernard, O. Stehlíková, D. Šálek, A. Janíková, J. Mayer, and M. Doubek, “Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach,” Cytometry B Clin Cytom, vol. 88, no. 2, pp. 92–100, Mar. 2015.

[4]  M. Doubek, Y. Brychtova, A. Panovska, L. Sebejova, O. Stehlikova, J. Chovancova, J. Malcikova, J. Smardova, K. Plevova, P. Volfova, M. Trbusek, M. Mraz, D. Bakesova, J. Trizuljak, M. Hadrabova, P. Obrtlikova, J. Karban, L. Smolej, A. Oltova, E. Jelinkova, S. Pospisilova, and J. Mayer, “Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study,” Am. J. Hematol., vol. 90, no. 5, pp. 417–421, May 2015.

[5]  O. Stehlíková, J. Chovancová, B. Tichý, M. Krejčí, Y. Brychtová, A. Panovská, H. Francová Skuhrová, K. Burčková, M. Borský, T. Loja, J. Mayer, S. Pospíšilová, and M. Doubek, “Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice,” Int J Lab Hematol, vol. 36, no. 2, pp. 165–171, Apr. 2014.


zde může být Vaše reklama logo Zbrojovky Brno logo Lékaři bez hranic



CZ ENG DE

změnit velikost písma

Jihlavská 20, 625 00 Brno
+420 532 23 1111
fnbrno@fnbrno.cz

NIAHOSM ISO 9001:2008 ISO 14001:2001